Skip to content
Search

Latest Stories

Gujarati boy in London needs help to overcome rare disease

A four-year-old Gujarati boy in London needs a stem cell donor as he suffers from a rare disease.

Veer has been diagnosed with a very rare genetic disorder called Fanconi Anaemia. It is a rare inherited disease that mainly affects the bone marrow.


It results in decreased production of all types of blood cells. This is the most common inherited form of aplastic anemia.

People with this condition may have bone marrow failure, physical abnormalities, organ defects, and an increased risk of certain cancers.

Family members said Veer needs a stem cell transplant to overcome this illness. Unfortunately, there are not enough donors on the national or international registers.

"His condition has deteriorated quicker than we expected and he needs a stem cell transplant sooner than expected," his parents said.

His family have been campaigning to raise awareness and increase stem cell donor registrations since 2018.

As he is of Indian heritage it is more difficult for him to find a matching stem cell donor. It is "critical that more people from a south Asian background sign up to register", they said.

Veer's plight highlights the importance of creating awareness about stem cell donation among south Asians in the UK.

His family has also set up FacebookTwitter and Instagram pages to support their son’s appeal and influencers and celebrities are now associated with the campaign.

For more details-https://www.helpveernow.org/

More For You

H1B programme

Brat has claimed that Chennai issued 220,000 H-1B visas despite the US cap of 85,000.

iStock

Economist alleges H-1B fraud as Chennai shows 220,000 approvals against US cap

AMERICA's H-1B visa system has come under renewed scrutiny after US economist and former Representative Dave Brat claimed that visa approvals had exceeded statutory limits.

Brat said on Steve Bannon’s War Room podcast that although the annual cap is 85,000, Chennai alone accounted for 220,000 H-1B approvals.

Keep ReadingShow less